Regulus Therapeutics Inc.

DB:7RG0 Stock Report

Market Cap: €99.7m

Regulus Therapeutics Management

Management criteria checks 2/4

Regulus Therapeutics' CEO is Jay Hagan, appointed in May 2017, has a tenure of 7.5 years. total yearly compensation is $2.57M, comprised of 23.9% salary and 76.1% bonuses, including company stock and options. directly owns 0.087% of the company’s shares, worth €86.89K. The average tenure of the management team and the board of directors is 5.3 years and 7.5 years respectively.

Key information

Jay Hagan

Chief executive officer

US$2.6m

Total compensation

CEO salary percentage23.9%
CEO tenure7.5yrs
CEO ownership0.09%
Management average tenure5.3yrs
Board average tenure7.5yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Jay Hagan's remuneration changed compared to Regulus Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$42m

Jun 30 2024n/an/a

-US$35m

Mar 31 2024n/an/a

-US$31m

Dec 31 2023US$3mUS$616k

-US$30m

Sep 30 2023n/an/a

-US$29m

Jun 30 2023n/an/a

-US$28m

Mar 31 2023n/an/a

-US$29m

Dec 31 2022US$1mUS$598k

-US$28m

Sep 30 2022n/an/a

-US$29m

Jun 30 2022n/an/a

-US$30m

Mar 31 2022n/an/a

-US$29m

Dec 31 2021US$2mUS$568k

-US$28m

Sep 30 2021n/an/a

-US$22m

Jun 30 2021n/an/a

-US$15m

Mar 31 2021n/an/a

-US$16m

Dec 31 2020US$2mUS$552k

-US$16m

Sep 30 2020n/an/a

-US$19m

Jun 30 2020n/an/a

-US$23m

Mar 31 2020n/an/a

-US$21m

Dec 31 2019US$2mUS$536k

-US$19m

Sep 30 2019n/an/a

-US$22m

Jun 30 2019n/an/a

-US$27m

Mar 31 2019n/an/a

-US$36m

Dec 31 2018US$2mUS$520k

-US$49m

Sep 30 2018n/an/a

-US$55m

Jun 30 2018n/an/a

-US$60m

Mar 31 2018n/an/a

-US$68m

Dec 31 2017US$2mUS$475k

-US$72m

Compensation vs Market: Jay's total compensation ($USD2.57M) is above average for companies of similar size in the German market ($USD475.63K).

Compensation vs Earnings: Jay's compensation has increased whilst the company is unprofitable.

CEO

Jay Hagan (55 yo)

7.5yrs

Tenure

US$2,574,323

Compensation

Mr. Joseph P. Hagan, also known as Jay, served as Independent Director of Zosano Pharma Corporation since May 22, 2015, until May 10, 2022. He has been the Chief Executive Officer and Director of Regulus T...

Leadership Team

NamePositionTenureCompensationOwnership
Joseph Hagan
CEO & Director7.5yrsUS$2.57m0.087%
€ 86.9k
Crispina Calsada
Chief Financial Officer5.3yrsUS$1.07m0.0088%
€ 8.8k
Christopher Aker
Senior VP13.8yrsUS$1.09m0.015%
€ 15.3k
Preston Klassen
President1.4yrsno data0%
€ 0
Daniel Penksa
VP of Finance & Controller5.3yrsno datano data
Claire Padgett
Senior Vice President of Clinical Operations2yrsno datano data
Rekha Garg
Chief Medical Officer2yrsno datano data
Edmund Lee
Vice President of Translational Medicineno datano datano data

5.3yrs

Average Tenure

55yo

Average Age

Experienced Management: 7RG0's management team is seasoned and experienced (5.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Joseph Hagan
CEO & Director7.5yrsUS$2.57m0.087%
€ 86.9k
Preston Klassen
President1.4yrsno data0%
€ 0
William Rastetter
Independent Director11.6yrsUS$99.44k0.060%
€ 59.4k
Timothy Wright
Member of the Scientific Advisory Board5.7yrsUS$1.48mno data
Stelios Papadopoulos
Independent Chairman of the Board15.8yrsUS$131.44k1.49%
€ 1.5m
David Baltimore
Chairman of the Scientific Advisory Board & Independent Director15.8yrsUS$95.44k0.0039%
€ 3.9k
Jason Nunn
Independent Director5.4yrsUS$97.44k0%
€ 0
Thomas Tuschl
Member of the Scientific Advisory Boardno datano datano data
Markus Stoffel
Member of the Scientific Advisory Boardno datano datano data
Hugh Rosen
Independent Director8.4yrsUS$93.44k0.0027%
€ 2.7k
Kathryn Collier
Independent Director6.6yrsUS$107.44k0.010%
€ 10.3k
Pascale Witz
Independent Director7.4yrsUS$93.44k0.0072%
€ 7.2k

7.5yrs

Average Tenure

61yo

Average Age

Experienced Board: 7RG0's board of directors are considered experienced (7.5 years average tenure).